Background/Objectives: This study aimed to develop a novel nanotechnological slowrelease drug delivery platform based on hyaluronic acid Microsponge (MSP) for the subcutaneous administration of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA). RA is a chronic autoimmune disease characterized by joint inflammation and damage, while MTX is a common disease-modifying antirheumatic drug (DMARD), the conventional use of which is limited by adverse effects and the lack of release control. Methods: MSP were synthesized as freeze-dried powder to increase their stability and allow for a facile reconstitution prior to administration and precise MTX dosing. Results: A highly stable and rounded-shaped micrometric MSP, characterized by an open porosity inner structure, achieved both a high MTX loading efficiency and a slow release of MTX after injection. Our drug release assays indeed demonstrated a characteristic drug release profile consisting of a very limited burst release in the first few hours, followed by a slow release of MTX sustained for over a month. By means of a preclinical rat model of RA, the administration of MTX-loaded MSPprovedto nearly double the therapeutic efficacy compared to sole MTX, according to a steep reduction in arthritic score compared to control groups. The preclinical study was replicated twice to confirm this improvement in performance and the safety profile of the MSP. Conclusions: This study suggests that the MSP drug delivery platform holds significant potential for clinical use in improving RAtherapy by enabling the sustained slow release of MTX, thereby enhancing therapeutic outcomes and minimizing side effects associated with conventional burst-release drug administration.

Fiaschini, N., Hanieh, P.n., Ariaudo, D., Cimino, R., Abbate, C., Romano, E., et al. (2024). Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy. PHARMACEUTICS, 16(12) [10.3390/pharmaceutics16121593].

Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy

Noemi Fiaschini;PATRIZIA NADIA HANIEH;Daniela Ariaudo;Rita Cimino;Carlo Abbate;Elena Romano;FRANCESCA CAVALIERI;MARIANO VENANZI;Manuel Scimeca;Roberta Bernardini;Maurizio Mattei;Antonio Rinaldi
2024-01-01

Abstract

Background/Objectives: This study aimed to develop a novel nanotechnological slowrelease drug delivery platform based on hyaluronic acid Microsponge (MSP) for the subcutaneous administration of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA). RA is a chronic autoimmune disease characterized by joint inflammation and damage, while MTX is a common disease-modifying antirheumatic drug (DMARD), the conventional use of which is limited by adverse effects and the lack of release control. Methods: MSP were synthesized as freeze-dried powder to increase their stability and allow for a facile reconstitution prior to administration and precise MTX dosing. Results: A highly stable and rounded-shaped micrometric MSP, characterized by an open porosity inner structure, achieved both a high MTX loading efficiency and a slow release of MTX after injection. Our drug release assays indeed demonstrated a characteristic drug release profile consisting of a very limited burst release in the first few hours, followed by a slow release of MTX sustained for over a month. By means of a preclinical rat model of RA, the administration of MTX-loaded MSPprovedto nearly double the therapeutic efficacy compared to sole MTX, according to a steep reduction in arthritic score compared to control groups. The preclinical study was replicated twice to confirm this improvement in performance and the safety profile of the MSP. Conclusions: This study suggests that the MSP drug delivery platform holds significant potential for clinical use in improving RAtherapy by enabling the sustained slow release of MTX, thereby enhancing therapeutic outcomes and minimizing side effects associated with conventional burst-release drug administration.
2024
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MEDS-02/A - Patologia generale
English
Con Impact Factor ISI
microsponge; rheumatoid arthritis; methotrexate; slow delivery system
Fiaschini, N., Hanieh, P.n., Ariaudo, D., Cimino, R., Abbate, C., Romano, E., et al. (2024). Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy. PHARMACEUTICS, 16(12) [10.3390/pharmaceutics16121593].
Fiaschini, N; Hanieh, Pn; Ariaudo, D; Cimino, R; Abbate, C; Romano, E; Cavalieri, F; Venanzi, M; Palumbo, V; Scimeca, M; Bernardini, R; Mattei, M; Mig...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-16-01593-v2.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 9.67 MB
Formato Adobe PDF
9.67 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/396943
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact